Cytek Biosciences, Inc. insider trading

Every open-market purchase and sale by Cytek Biosciences, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Cytek Biosciences, Inc.’s insiders pay?

From February 16, 2022 to June 3, 2025, 5 insiders reported 8 open-market purchases and 0 sales not made under a pre-set plan in Cytek Biosciences, Inc. Twelve months after each purchase was reported, the shares were −17.5% against the S&P 500 on average (median −18.6%), over 7 purchases with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 17, 2022 into $7,583 by November 2, 2026, −5.7% a year. It held shares 23% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $10,768 (+1.6% a year), and held throughout $18,441 (+14.0%).

Copying Cytek Biosciences, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Cytek Biosciences, Inc.'s insiders from February 17, 2022, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 23% of the time.

Cytek Biosciences, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Shah Rajeev M.	Director	4	−16.5% (4)	0%	—	March 11, 2022
Mccombe William D.	Chief Financial Officer	1	—	—	—	June 3, 2025
Ra Capital Healthcare Fund LP	Director	1	−15.5% (1)	0%	—	March 16, 2022
Ra Capital Management, L.P.	Director	1	−18.8% (1)	0%	—	February 16, 2022
Ra Capital Nexus Fund II, L.P.	Director	1	−22.3% (1)	0%	—	February 25, 2022

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Cytek Biosciences, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Cytek Biosciences, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −7.6% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
February 28, 2022	3 buying	−21.4%	−7.6%	−22.3%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Cytek Biosciences, Inc. · Funds · Politicians